Abstract
The authors review and discuss the opportunities and challenges raised by policy options for Average Sales Price reform or replacement.
MeSH terms
-
Antineoplastic Agents / economics*
-
Antineoplastic Agents / therapeutic use
-
Commerce
-
Cost Savings
-
Drug Costs
-
Episode of Care
-
Health Care Reform
-
Health Policy / economics
-
Humans
-
Medicare / economics
-
Neoplasms / drug therapy
-
Neoplasms / economics*
-
Reimbursement Mechanisms / economics
-
United States